The serum of humans and of mice with systemic lupus erythematosus (SLE) contains autoantibodies of many specificities, nearly all cell associated (1). The preferential detection of autoantibodies to cellular antigens may not be due solely to a special predilection to produce such antibodies in SLE, but might be also a consequence of in vivo absorption of other autoantibodies by self-antigens present in serum in high molar concentrations. Cell-associated autoantigens, in contrast, would be either relatively inaccessible to circulating autoantibodies (if intracellular) or present in sufficiently low serum concentrations to escape in vivo absorption.
of protein at a concentration of 1 mg/ml in normal saline. Chromic chloride (Mallinckrodt, Inc., St. Louis, MO) was then added, generally at 1 mg/ml in normal saline, although optimal concentrations were determined empirically for each protein. After 15 min at room temperature, the erythrocytes were washed three times before use. The presence of protein on the conjugated erythrocytes was determined for each batch by passive hemagglutination using appropriate goat or rabbit reference antisera against mouse serum, mouse transferrin (U.S. Biochemical Corp.), or human, bovine, dog, or hamster strum (Cappel Laboratories). Spleen cells to be assayed for autoantibody plaque-forming cells (PFC) were suspended to 1 X 106/ml in Hanks' balanced salt solution (University of North Carolina Cancer Center, Chapel Hill, NC). 100 ~1 of cell suspension were mixed with 10 ~1 of 10% erythrocyte suspension in the wells of flat-bottom microtiter plates (Costar, Data Packaging, Cambridge, MA) and the plates spun for 10 min at 200 g and then for 5 min at 400 g. The resulting suspensions of lymphocytes and erythrocytes were allowed to incubate for 1 h, at which point was added 10 IA of a 1 : 10 dilution of the IgG fraction of a rabbit anti-mouse IgG antiserum, together with sufficient guinea pig complement to achieve a final 1:13 concentration. After 1 h incubation at 37 o C, hemolytic plaques were scored with a stereo microscope. Controls, i.e., uncoupled sheep erythrocyte suspensions and wells without added lymphocytes, were performed for each experiment to assure that plaques were not artifactual.
Results

Quantitation of PFC Against Autologous Proteins.
The spleens of MRL/Mp-lpr/ lpr, BXSB, and NZB mice were found to contain substantial numbers of PFC against purified mouse albumin and mouse transferrin (Table I ). All antitransferrin and antialbumin PFC required rabbit anti-mouse IgG for visualization and thus represented IgG PFC. In contrast, much smaller numbers were found in spleens of mice that did not suffer from autoimmune disease. A requirement for protein synthesis was indicated by the finding that 4-h pretreatment of spleen cells with cycloheximide (100 #g/ml) decreased PFC ~85%. MRL/Mp-lpr/lpr mice and 9 BXSB mice. 10 additional experiments using normal mice yielded similar low numbers of PFC. 
Specificity of PFC Against Serum Proteins.
To determine whether the antimouse protein PFC were primarily directed against murine autoantigens, we performed inhibition studies. The specificity of anti-mouse albumin PFC in MRL/Mp-lpr/lpr mice is shown in Fig. 1 . In this experiment, graded amounts of albumin from various species were added to the assay system in an effort to inhibit plaques with soluble antigen. Mouse albumin was the most inhibitory preparation, followed by cow and human; no inhibition of plaques was seen with ovalbumin. Thus, antibody secreted was relatively specific for mouse albumin and therefore truly autoreactive. Similar experiments (Fig. 2) were performed in the mouse transferrin system. It was noted that, while human transferrin did not inhibit mouse transferrin PFC even at concentrations >1 mg/ml, bovine transferrin was approximately equivalent to mouse transferrin in inhibiting mouse transferrin PFC, indicating crossreactivity between the anti-mouse transferrin autoantibody and bovine transferrin. Similar results were obtained when bovine transferrin was used on the indicator erythrocytes (not shown). Therefore, bovine transferrin appeared to react extensively with mouse autoantibody to transferrin, while human transferrin was not crossreactive. 
Comparsion of PFC Against Foreign Serum Proteins With Autologous PFC. Polyclonal activation of B cells has been shown to result in formation of
autoantibodies (5) . If this mechanism contributed to the formation of autoantibodies to transferrin, independent of autoantigen, that it would be anticipated that autoantibodies to transferrins of other species would also be produced as a consequence of the generalized activation of B cells. Alternatively, if a process other than global activation of B cells (i.e., an antigen-driven immune response) were responsible for the production of anti-mouse transferrin in autoimmune mice, then relatively few PFC directed against heterologous noncrossreactive transferrin would be seen. In Fig. 3 , it is seen that, while roughly equivalent numbers of PFC were present for the crossreactive mouse and bovine transferrins, there were few PFC seen against human transferrin. Rabbit, hamster, and dog transferrins, which are partially crossreactive with the mouse autoantibody (based on their capacity to inhibit mouse transferrin PFC), when coupled to sheep red blood cells, were able to detect varying numbers of PFC. The results provide evidence against polyclonai B cell activation as the mechanism ofautoantibody formation, since PFC were seen mainly against those transferrins known to crossreact with the true autoantibody.
Detection of Serum Antialbumin and Antitransferrin by ELISA Assay. Assays were developed to detect circulating antibody against mouse albumin and transferrin, using sensitive enzyme-linked immunosorbent assay (ELISA) technology. Sera from lpr mice reproducibly gave more binding to mouse albumin-or transferrincoated plates than did normal mouse serum, yet normal samples always contained some transferrin-binding immunoglobulin. Extensive efforts were made to inhibit the binding both of normal and lpr sera with free transferrin, at concentrations as high as 1 mg/ml. In no case could the binding be inhibited, indicating that the circulating antibody probably was of low avidity. Discussion The present data indicate that there is substantial spontaneous production of autoantibody to serum proteins in spleens of autoimmune mice. Although small amounts of such antibodies are detectable in the serum, the inability of free antigen to inhibit them indicates that the free antibody is of low avidity.
The observation that the autoimmune mice produce antibodies to serum proteins as well as to cell-bound antigen suggests that autoantibody production in murine lupus is a more generalized phenomenon than previously believed and that the spectrum of SLE autoantibodies should be widened to include not only those directed against constituents of cells, but also those directed against serum proteins. The data contrast with recent views (6) that the autoantibodies observed in SLE may represent a much more limited repertoire of molecules with interesting polyspecificities.
The present study also shows that the autoantibodies detected here at the cellular level are relatively specific for autologous proteins. The hypothesis that autoantibody production in those strains is merely a consequence of diffuse polyclonal B cell activation cannot explain these findings, since one would then anticipate equivalent production of antibodies to transferrins of different species. Furthermore, while it is true that the production of polyclonal antibodies to many exogenous antigens is characteristic of murine lupus, such antibodies are generally elevated only two-or threefold (7) . For both quantitative and qualitative reasons, such a global increase in antibody production would not explain the production of autoantibodies to serum proteins that are specifically directed against autologous serum proteins. The mechanism responsible must be able to cause general production of autoantibodies that are specific for the species. These data are best explained by assuming that autoantigens themselves drive the autoantibody response and that, in the presence of a regulatory abnormality, the production of each individual autoantibody is due to antigen-specific events rather than diffuse activation of B cells by polyclonal B cell activators of T or non-T cell origin.
Since the autoantibodies against serum proteins described herein are probably incorporated into immune complexes shortly after antibody secretion because of the availability of antigen, such complexes may be involved in the genesis of giomerular injury and other immune complex effects. In addition, it is possible that some species of transferrin autoantibodies interfere with iron binding, or with the cell growth-regulating properties of transferrin, and thus possibly contribute to anemia or disordered cell replication in SLE.
